Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hogg

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2017
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 CasesAbhijat Kitchlu, Warren Fingrut, Carmen Avila-Casado, et al.
Melanoma Research|August 2, 2018
Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experienceMathew N Nicholas, Leila Khoja, Eshetu G Atenafu, et al.
Kidney Medicine|May 5, 2022
Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case ReportSonia Rodriguez-Ramirez, Kevin Yau, Abhijat Kitchlu, et al.
Cancer Immunology Research|October 1, 2015
Subacute CNS Demyelination after Treatment with Nivolumab for MelanomaCatherine Maurice, Raphael Schneider, Tim-Rasmus Kiehl, et al.
Oncology Letters|February 20, 2016
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanomaLeila Khoja, Eshetu G Atenafu, Qian Ye, et al.
British Journal of Cancer|October 5, 2016
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patientsLeila Khoja, Minnie Kibiro, Ur Metser, et al.
Genes, Chromosomes & Cancer|December 16, 2006
The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestryJulie Lang, Nicholas Hayward, David Goldgar, et al.
Current Oncology (Toronto, Ont.)|July 2, 2021
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse EventsDaniel V Araujo, Thiago Pimentel Muniz, Anjie Yang, et al.
Heart (British Cardiac Society)|October 5, 2021
Prediction of incident atrial fibrillation in community-based electronic health records: a systematic review with meta-analysisRamesh Nadarajah, Eman Alsaeed, Ben Hurdus, et al.
Cancer Medicine|September 30, 2016
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanomaLeila Khoja, Eshetu G Atenafu, Arnoud Templeton, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2017
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 CasesAbhijat Kitchlu, Warren Fingrut, Carmen Avila-Casado, et al.
Melanoma Research|August 2, 2018
Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experienceMathew N Nicholas, Leila Khoja, Eshetu G Atenafu, et al.
Kidney Medicine|May 5, 2022
Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case ReportSonia Rodriguez-Ramirez, Kevin Yau, Abhijat Kitchlu, et al.
Cancer Immunology Research|October 1, 2015
Subacute CNS Demyelination after Treatment with Nivolumab for MelanomaCatherine Maurice, Raphael Schneider, Tim-Rasmus Kiehl, et al.
Oncology Letters|February 20, 2016
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanomaLeila Khoja, Eshetu G Atenafu, Qian Ye, et al.
British Journal of Cancer|October 5, 2016
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patientsLeila Khoja, Minnie Kibiro, Ur Metser, et al.
Genes, Chromosomes & Cancer|December 16, 2006
The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestryJulie Lang, Nicholas Hayward, David Goldgar, et al.
Current Oncology (Toronto, Ont.)|July 2, 2021
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse EventsDaniel V Araujo, Thiago Pimentel Muniz, Anjie Yang, et al.
Heart (British Cardiac Society)|October 5, 2021
Prediction of incident atrial fibrillation in community-based electronic health records: a systematic review with meta-analysisRamesh Nadarajah, Eman Alsaeed, Ben Hurdus, et al.
Cancer Medicine|September 30, 2016
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanomaLeila Khoja, Eshetu G Atenafu, Arnoud Templeton, et al.
Pageof 8